GLOBAL LIVER INSTITUTE
Over the past decade, the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD, previously known as nonalcoholic fatty liver disease/NAFLD) in children has seen a concerning rise.
The GLI Pediatric and Rare Liver Diseases team was thrilled to attend the BARE Symposium on May 10-11, 2024.
June 13 marks Global Fatty Liver Day, and the time to act is NOW! With conditions like obesity and diabetes increasing the risk for fatty liver disease, early screening is absolutely crucial.
Fatty liver disease includes a spectrum of liver conditions characterized by excess fat accumulation in the liver of individuals. It encompasses a range of conditions, from simple steatosis (fatty liver) to nonalcoholic steatohepatitis (NASH), as well as nonalcoholic fatty liver disease (NAFLD) which can progress to cirrhosis, liver failure, and hepatocellular carcinoma.
Genentech/Roche is enhancing the accessibility of clinical trials by providing comprehensive patient support services. By tackling common barriers to participation – such as travel costs, distance, parking, childcare, conflicting work schedules, health literacy, site location, capabilities, expectations, and privacy concerns – they aim to make clinical trials more inclusive and representative.
Global Liver Institute applauds U.S. Representative Nydia Velázquez (D-NY) for reintroducing this vital legislation to improve the lives of all people impacted by liver disease. GLI was proud to collaborate in the development of The Liver Illness, Visibility, Education and Research Act (LIVER Act), first introduced in 2018.
Global Liver Institute (GLI) convened esteemed global leaders for an event on the sidelines of the 77th World Health Assembly in Geneva, Switzerland, entitled “Together for Better Liver Health: Amplifying Best Practices Globally,” in partnership with the European Association for the Study of the Liver (EASL).
Viral hepatitis, a group of infections affecting the liver, has long been a global health concern. As the seventh leading cause of death worldwide it stands out as the only communicable disease with rising mortality.
In the post-election work period, “must-do” program reauthorizations are expected to be considered. Lawmakers will be eyeing action on these health care policies and more during the “lame duck” session after the November elections and before the 118th Congress gavels out.
In April, GLI Program Director Kristin Hatcher was invited to engage with patient advocacy groups, industry partners, and patients during the PBC Foundation’s International Summit in Edinburgh, Scotland.
At the Academy of Managed Care Pharmacy meeting on April 16, experts discussed the emerging landscape of NASH treatments, focusing on the recent approval of Madrigal’s Rezdiffra.
GLI applauds the announcement of a federally-funded study by the Agency for Healthcare Research and Quality (AHRQ) to assess the prevalence of fatty liver disease (known as metabolic-associated fatty liver disease or nonalcoholic fatty liver disease) as well as its associated costs and barriers in the US.
